Janus kinases (JAKs) belong to the non-receptor tyrosine kinase family, and their JAK-STAT signaling pathway with signal transducers and activators of transcription (STAT) can affect cell proliferation, differentiation, apoptosis, and […]
Fostamatinib is the precursor drug of active metabolite R406. It is a Syk inhibitor with an IC50 value of 41 nM. It strongly inhibits Syk but does not inhibit Lyn. […]
Dabrafenib (GSK2118436) is a mutant BRAFV600-specific inhibitor, with an IC50 of 0.7 nM in cell-free assays. It shows 7-fold and 9-fold lower potency against B-Raf(wt) and c-Raf, respectively. Synthetic route: […]
Kinase inhibitors can be divided into monoclonal antibodies (mAbs) and small molecule kinase inhibitors (SMKIs) based on their structure and size. Monoclonal antibodies have achieved great success in the development […]
Existing research shows that nucleic acids can be used for the treatment of neurological diseases, cardiovascular diseases, and cancer, as well as for the prevention of chronic and infectious diseases. […]
B7-H3 and B7-H4 are type I transmembrane proteins belonging to the B7 family. Their abnormal expression is associated with many diseases such as colon cancer, breast cancer, liver cancer, and […]
Introduction to HER and ADCs Members of the human epidermal growth factor receptor (HER) family, including HER1 (EGFR), HER2, HER3, and HER4, play a core role in regulating cell proliferation, […]
Pfizer’s mRNA vaccine for COVID has reignited the passion for using ribonucleic acid (RNA) as a therapeutic target. However, targeting RNA with small molecules is extremely challenging. RNA only has […]
The core technologies of oligonucleotide drug development include sequence design, synthesis and modification, isolation and purification, and delivery techniques. The production of oligonucleotide raw materials adopts solid-phase synthesis technology, with […]